title: The dopamine D2 receptor regulates Akt and GSK-3 via Dvl-3.
abstract: The dopamine D2 receptor (D2DR) regulates Akt and may also target the Wnt pathway, two signalling cascades that inhibit glycogen synthase kinase-3 (GSK-3). This study examined whether the Wnt pathway is regulated by D2DR and the role of Akt and dishevelled-3 (Dvl-3) in regulating GSK-3 and the transcription factor β-catenin in the rat brain. Western blotting showed that subchronic treatment of raclopride (D2DR antagonist) increase phosphorylated Akt, Dvl-3, GSK-3, phosphorylated GSK-3 and β-catenin, whereas subchronic treatment of quinpirole (D2DR agonist) induced the opposite response. Co-immunopreciptations revealed an association between GSK-3 and the D2DR complex that was altered following raclopride and quinpirole, albeit in opposite directions. SCH23390 (D1DR antagonist) and nafadotride (D3DR antagonist) were also used to determine if the response was specific to the D2DR. Neither subchronic treatment affected Dvl-3, GSK-3, Akt nor β-catenin protein levels, although nafadotride altered the phosphorylation state of Akt and GSK-3. In addition, in-vitro experiments were conducted to manipulate Akt and Dvl-3 activity in SH-SY5Y cells to elucidate how the pattern of change observed following manipulation of D2DR developed. Results indicate that Akt affects the phosphorylation state of GSK-3 but has no effect on β-catenin levels. However, altering Dvl-3 levels resulted in changes in Akt and the Wnt pathway similar to what was observed following raclopride or quinpirole treatment. Collectively, the data suggests that the D2DR very specifically regulates Wnt and Akt signalling via Dvl-3.
authors.affiliation: Department of Anatomy and Cell Biology, University of Western Ontario and the London Health Sciences Center, London, ON, Canada.
authors.forename: Laurie P
authors.initials: LP
authors.lastname: Sutton
authors.forename: Walter J
authors.initials: WJ
authors.lastname: Rushlow
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000378:metabolism*; D000730:Androstadienes / Q000494:pharmacology; D000818:Animals; D045744:Cell Line, Tumor; D000072261:Dishevelled Proteins; D015259:Dopamine Agents / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects; D038362:Glycogen Synthase Kinase 3 / Q000378:metabolism*; D047468:Immunoprecipitation; D008297:Male; D009447:Neuroblastoma / Q000473:pathology; D051058:Oncogene Protein v-akt / Q000378:metabolism*; D010750:Phosphoproteins / Q000378:metabolism*; D010766:Phosphorylation / Q000187:drug effects / Q000235:genetics; D017397:Prefrontal Cortex / Q000187:drug effects / Q000378:metabolism*; D034741:RNA, Small Interfering / Q000378:metabolism / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D014162:Transfection; D000077191:Wortmannin; D051176:beta Catenin / Q000378:metabolism
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000730:Androstadienes; C495268:Ctnnb1 protein, rat; D000072261:Dishevelled Proteins; D015259:Dopamine Agents; D004791:Enzyme Inhibitors; D010750:Phosphoproteins; D034741:RNA, Small Interfering; D017448:Receptors, Dopamine D2; D051176:beta Catenin; D051058:Oncogene Protein v-akt; D038362:Glycogen Synthase Kinase 3; D000077191:Wortmannin